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ABSTRAK
Tujuan: untuk mengetahui perbedaan kadar matrix metalloproteinase-9 (MMP-9) serum pada pasien sindroma 
koroner akut dengan dan tanpa hiperglikemia. Metode: desain penelitian ini merupakan potong-lintang pada pasien 
dengan sindroma koroner akut yang dirawat di ICCU Rumah Sakit Dr. Sardjito Yogyakarta Indonesia. Pencuplikan 
subjek dilakukan secara berurutan. Pengukuran kadar glukosa darah dilakukan saat masuk rumah sakit dan 
MMP-9 dilakukan sesaat setelah tiba di ICCU. Glukosa darah >140 mg/dL ditetapkan sebagai hiperglikemia. Uji 
Student t digunakan untuk menganalisis perbedaan kadar MMP-9 antara subjek dengan dan tanpa hiperglikemia. 
Hasil: dari 72 subjek penelitian, 34 subjek dengan hiperglikemia dan 38 subjek tanpa hiperglikemia. Rerata kadar 
glukosa darah berbeda signifikan antara subjek dengan dan tanpa hiperglikemia (204,4±92.16 vs. 108,93±19,1 mg/
dL, p=0,0001). Rerata kadar MMP-9 pada subjek dengan hiperglikemia secara signifikan lebih tinggi daripada 
subjek tanpa hiperglikemia (1574±573,61 ng/mL vs. 1370±573,66 ng/mL, p=0,025). Rasio prevalensi MMP-9 tinggi 
diantara subjek dengan hiperglikemia mencapai 2,88 (95% CI: 1,16–7,14), p=0.004. Kesimpulan: kadar MMP-
9 serum pada pasien sindroma koroner akut dengan hiperglikemia secara signifikan lebih tinggi dibandingkan 
pasien tanpa hiperglikemia.
Kata kunci: sindrom koroner akut, matriks metaloproteinase-9, hiperglikemia.
ABSTRACT
Aim: to determine the difference in serum matrix metalloproteinase-9 (MMP-9) levels among acute coronary 
syndrome patients with and without hyperglycemia. Methods: this study was a cross-sectional study on patients 
with acute coronary syndrome admitted to ICCU of Dr.Sardjito Hospital Yogyakarta Indonesia. Measurements of 
blood glucose level were performed on hospital admission, while measurement of MMP-9 level was performed 
upon arrival at the ICCU. Hyperglycemia was defined as a random blood glucose level of >140 mg/dL. Student’s 
t test was performed to analyze the difference of MMP-9 level between subjects with and without hyperglycemia. 
Results: of 72 enrolled subjects, there were 34 subjects with hyperglycemia and 38 subjects without hyperglycemia. 
The mean blood glucose level was significantly different in subjects with hyperglycemia as compared to those 
without hyperglycemia (204.4±92.16 vs. 108.93±19.1 mg/dL, p=0.0001). The mean MMP-9 level in subjects with 
hyperglycemia was significantly higher than those without hyperglycemia (1574±573.61 vs. 1370±573.66 ng/
mL, p=0.025). The prevalence ratio of high MMP-9 level among subjects with hyperglycemia was 2.88 (95% CI: 
1.16-7.14), p=0.004. Conclusion: serum MMP-9 level in patients suffering from acute coronary syndrome with 
hyperglycemia was significantly higher than those without hyperglycemia.
Key words: acute coronary syndrome, matrix metalloproteinase-9, hyperglycemia.
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INTRODUCTION
Previous studies have demonstrated that 
hyperglycemia is often found upon hospital 
admission in patients with acute coronary 
syndrome. Hyperglycemia is one of the risk 
factors for mortality and complications during 
hospitalization.1,2 Despite the varied definitions of 
hyperglycemia, the prevalence of hyperglycemia 
in acute coronary syndrome ranges from 25% to 
50%.1-3 Increased long-term mortality and larger 
infarct size in patients with acute myocardial 
infarction have been associated with in-hospital 
hyperglycemia. Previous diabetes mellitus is 
also a risk factor for developing hyperglycemia 
during episodes of acute coronary syndrome.4
Coronary heart disease causes myocardial 
ischemia with diverse clinical spectrums, 
namely ischemia without symptoms (silent 
ischemia), stable angina pectoris, acute coronary 
syndrome, heart failure and sudden cardiac death. 
Atherosclerosis is the underlying pathology in 
acute coronary syndromes.5 Pathophysiology 
of coronary atherosclerosis involves an 
inflammation process. A number of inflammatory 
biomarkers have been investigated in association 
with plaque instability, one of which is matrix 
metalloproteinase (MMP) system.6
MMP are proteolytic enzymes which 
cause degradation of the extracellular matrix, 
resulting in tissue remodeling during normal 
biological processes. Vascular remodeling is 
now recognized as a major determinant for 
vascular pathologies including atherosclerosis 
and restenosis. It is widely accepted that the 
disregulation of the MMP system plays an 
important role in vascular remodeling and 
atherosclerosis.7 Furthermore, MMP system is 
increased in vascular wall of diabetic patients 
which implies that chronic hyperglycemia may 
induce MMP-mediated atherosclerosis.8
Among MMPs, MMP-9 plays an important 
role in the degradation of extracellular matrix. 
Its activity is increased during rupture of 
atherosclerotic plaques which causes acute 
coronary syndrome.9 In patients with acute 
coronary syndrome, serum MMP-9 levels 
elevates in coronary and systemic circulation.9 
On the other hand, acute hyperglycemia is 
frequently found in acute coronary syndrome.1,2 
Acute hyperglycemia may induce elevated MMP 
expression in large vessels due to its effect 
on oxidative stress and RAGE production.10 
Previous study showed reduced serum MMP-9 
levels among diabetic patients.11 However the 
impacts of acute hyperglycemia, such as in acute 
coronary syndrome, on serum MMP levels have 
not yet been established.
Our study was conducted to determine 
whether there were differences of serum 
MMP-9 levels among patients suffering from 
acute coronary syndrome with and without 
hyperglycemia.
METHODS 
The study was a cross-sectional study 
conducted at Dr. Sardjito Hospital, Yogyakarta 
Indonesia. Target population of the study 
was patients suffering from acute coronary 
syndrome with hyperglycemia (random blood 
glucose levels of >140 mg/dL) and without 
hyperglycemia (random blood glucose levels of 
≤140 mg/dL) who were hospitalized at the ICCU. 
Cut-off value for random blood glucose levels 
was in accordance with previous publication.12 
Subjects were enrolled consecutively.
Inclusion criteria of our study were: (1) 
patients with acute coronary syndrome, including 
those with ST elevation myocardial infarction 
(STEMI), non-ST elevation myocardial infarction 
(NSTEMI) and unstable angina pectoris (UAP); 
(2) the onset of symptom ≤24 hours; (3) male 
and female patients with age of >20 years 
and (4) patients who agreed to participate in 
the study by signing the informed consent 
form. Exclusion criteria of the study were: (1) 
patients with chronic renal failure requiring 
renal replacement therapy, chronic congestive 
heart failure, liver cirrhosis, previous heart valve 
disease, acute stroke, acute complications of 
diabetes mellitus, acute exacerbation of chronic 
obstructive pulmonary disease, pneumonia, 
sepsis, chronic inflammatory disease, venous 
thromboembolic disease and malignancy, and 
(2) pregnant women.
The study was approved by The Ethical 
Committee of Faculty of Medicine, Universitas 
Gadjah Mada, Yogyakarta, Indonesia. 
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Diagnostic and Laboratory Examination
Diagnosis of acute coronary syndrome was 
established based on the diagnostic criteria of 
acute coronary syndrome, i.e. the typical chest 
pain, ST-T changes on 12 ECG leads, and presence 
or absence of elevated levels of CKMB and/or 
troponin I. Clinical and demographic data were 
recorded in the case report form upon hospital 
admission. Blood sampling for standard laboratory 
tests, including glucose level, were taken in the 
emergency room upon hospital admission. 
Laboratory tests were carried out in the Clinical 
Pathology Laboratory, Dr. Sardjito Hospital. 
Blood sampling for MMP-9 levels measurement 
were taken at the ICCU on the first day of arrival. 
Blood samples were withdrawn from the forearm 
in the supine position with a vacutainer, which 
allowed the blood to clot and be extracted for its 
serum.The sample was then centrifuged and the 
supernatan was stored at -80oC, until it was ready 
for the MMP-9 assay. Examination of MMP-9 was 
conducted by ELISA methods with a Quantikine 
Human MMP-9 Immunoassay (R & D Systems, 
Minneapolis, USA).
Statistical Analysis
Characteristics of subjects were described 
in mean value and standard deviation (SD) 
or median (minimal – maximal value) for 
continuous data based on the data distribution 
pattern. To analyze differences in mean value 
between two groups, we used Student’s T test or 
Mann-Whitney U Test. The data were analysed 
for normality with Shapiro-Wilk test. Categorical 
data were presented in proportion. To evaluate 
the difference in proportion among both groups, 
we used chi-squared test or Fisher’s Exact Test. 
A statistical significance was set at p<0.05.
RESULTS
There were 72 subjects with acute coronary 
syndrome enrolled in the study. Among them, 34 
subjects had hyperglycemia whereas 38 subjects 
had no hyperglycemia. The mean age of all 
subjects was 57.66 years, there was no significant 
difference of ages between subjects with and 
without hyperglycemia. The majority of subjects 
were males and accounted for almost 90% of all 
subjects. Ninety subjects (26.4 %) had diabetes 
mellitus, 47 subjects (65.3 %) had dyslipidemia, 
44 subjects (61.1%) had hypertension and 22 
subjects (30.6 %) were active smokers. 
The median value of serum MMP-9 levels in 
all subjects was 1289 ng/mL. Furthermore, the 
mean value of MMP-9 levels in subjects with 
hyperglycemia was 1574±573.61 ng/mL; while 
in subjects without hyperglycemia, the mean 
MMP-9 levels was lower, i.e. 1370±573.66 ng/
mL. The difference was statistically significant 
(p=0.02) (Table 1).
To determine the cut-off value of MMP-9 
levels for predicting hyperglycemia, we used the 
Receiver Operator Characteristic (ROC) curve 
analysis. From the ROC curve (Figure 1), we 
found that the cut-off value of MMP-9 levels 
was best fitted at 1014.25 ng/mL, which gave 
a sensitivity of 88.2%, specificity of 59.2% and 
area under the curve (AUC) of 65%. 
Figure 1. ROC curve to determine the cut-off value of MMP-9
Based on the cut-off value for MMP-9 level, 
the subjects were categorized into 2 groups, 
i.e. those with high MMP-9 levels who had 
the levels above the cut-off value (52 subjects) 
and those with low MMP-9 levels, who had 
the levels under the cut-off value (20 subjects). 
The proportion of high MMP-9 levels among 
subjects with hyperglycemia was significantly 
higher compared to the proportion among those 
without hyperglycemia (p=0.004). High MMP-9 
level was associated with hyperglycemia, which 
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contributed to prevalence ratio of 2.88 (95% CI: 
1.16-7.14), p=0.004. (Table 2)
DISCUSSION
Our study result showed that the MMP-9 
levels were significantly higher among patients 
with acute coronary syndrome who also had 
increased blood glucose levels. Furthermore, the 
serum MMP-9 levels were found to be almost 
three times higher in patients with hyperglycemia 
than those with normal blood glucose levels. The 
result highlighted the notion that blood glucose 
levels may affect the release of MMP-9 from 
ruptured atherosclerotic plaque.
Previous study has indicated that there is an 
increased MMP-9 levels in patients with acute 
coronary syndrome compared to healthy people.13 
A study by Garvin et al.14 showed that MMP-9 
levels increased in individuals with dyslipidemia, 
obesity, diabetes mellitus, smoking, alcohol 
Table 1. Characteristics of the subjects
Characteristics All Subjects (n=72) With Hyperglycemia(n=34)
Without Hyperglycemia 
(n=38)
Age (years) 57.66±10.87 57.31±11.6 57.69±10.44
Sex, n(%)
 - Male 64 (88.9) 31 (91.1) 33 (86.8)
 - Female 8 (11.1) 3 (8.9) 5 (13.1)
Diagnosis, n(%)
 - STEMI 38 (52.8) 22 (64.7) 16 (42,.1)
 - NSTEMI 15 (20.8) 5 (14.7) 10 (26.3)
 - UAP 19 (26.4) 7 (20.6) 12 (31.6)
Previous disease, n(%)
 - Hypertension 44 (61.1) 21 (61.7) 23 (60.5)
 - Dyslipidemia 47 (65.3) 23 (67.6) 24 (63.1)
 - Diabetes mellitus 19 (26.4) 17 (50) 2 (5.2)
 - Stable Angina Pectoris 20 (27.8) 6 (17.6) 14 (36.8)
Smoking, n(%)
 - Smoking 22 (30.6) 12 (35.3) 10 (26.3)
 - Non smoking 13 (18.1) 6 (17.6) 7 (18.4)
 - Ex Smoker 37 (51.4) 16 (47.1) 21 (55.3)
Killip class , n(%)
 - Killip I 61 (84.7) 27 (79.5) 34 (89.5)
 - Killip II-IV 11 (15.3) 7 (20.5) 4 (10.5)
Body mass index (kg/m2) 22.54(18.36-33.79)* 23.07±2.28 23.48±3.26
Onset (hour) 5 (1.5-24)* 7.03±6.12 7.44±7.11
Blood pressure (mmHg)
 - Systolic 129.52±28.08 128.78±26.4 128.2±30.77
 - Diastolic 78±15.66 76.8±15.7 79.1±16.36
Glucose (mg/dL) 139 (48-604)* 204.4±92.16 108.93±19.1
MMP-9 (ng/mL) 1289 (335.7-2556)* 1574±573.61 1370±573.66
Creatinine (mg/dL) 1.19 (0.47-7.5)* 1.4±0.62 1.5±1.23
Cholesterol (mg/dL) 197.56±50.77 202.8±56.75 195.7±44.2
LDL (mg/dL) 125.5 (53-291)* 125±47.03 127.73±40.8
Triglyceride (mg/dL) 116 (26-641)* 150.2±114.3 129.8±70.7
HDL (mg/dL) 37 (9.6-88)* 38.39±10.14 40.07±13.82
Continuous data is presented in mean±SD, categorical data was presented in proportion (n(%)); * = data distribution was 
not normal and presented as median (minimum-maximum); NA = not applicable
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consumption, low physical activity and low 
consumption of fibers.14 DeRosa et al.15 showed 
that those with dyslipidemia had significantly 
higher level of MMP-9 than healthy subjects.15 
In Indonesia, a recent study has demonstrated 
that dyslipidemia and metabolic syndrome has 
emerged, especially in urban area.16 Therefore, 
it is expected that dyslipidemic patients will 
be frequently encountered in acute coronary 
syndrome patients since dyslipidemia is one of 
the most important risk factors for coronary heart 
disease. The proportion of dyslipidemia in our 
study was relatively high, i.e. 65%; however, 
there was no significant difference between 
patients with and without hyperglycemia.
Obesity may affect MMP-9 levels. DeRosa 
et al.17 showed that MMP-9 levels in obese 
patients were significantly higher than in the 
control group (p<0.0001).17 In our study, the 
mean body mass index between subjects with 
hyperglycemia and without hyperglycemia 
was comparable. Based on body mass index, 
the proportion of obese patients in our study 
was small. Furthermore, increased MMP-9 
levels has also been identified in patients with 
hypertension, which reflects the magnitude 
of deposition and retention of type I collagen 
and other extracellular matrix in vascular 
wall leading to increased vascular tone.18 The 
proportion of hypertension in our study was quite 
high, i.e. 61%, which was comparable between 
patients with and without hyperglycemia. Taken 
together, obesity and hypertension in our study 
were not responsible for the different levels of 
MMP-9 observed among subjects with varied 
glucose levels.
Several previous studies have shown 
elevated MMP-9 levels in patients with type-2 
diabetes mellitus.19-21 However, other studies 
indicated the opposite.11,22 The conflicting results 
imply the complexity of glucose toxicity and 
insulin resistance in affecting MMP-9 turnover 
especially in chronic condition. In our study, the 
proportion of diabetes mellitus in all subjects was 
rather low, i.e. 26%. The majority of diabetic 
patients had increased blood glucose levels with 
a comorbidity of acute coronary syndrome (17 
out of 19 patients).
In subjects with hyperglycemia, diabetic 
patients account for half of the patients. This 
chronic hyperglycemic state may have a 
contribution in increased MMP-9 levels among 
patients with hyperglycemia. MMP system 
in the vascular wall is activated in chronic 
hyperglycemia.8 Lewandowski et al.11 has 
provided evidences that in patients with type-2 
diabetes mellitus, circulating MMP-9 levels were 
more affected by chronic hyperglycemic condition 
rather than by acute hyperglycemia.11 They 
showed the linear correlation between HbA1c 
and MMP-9 levels.11 Another experimental study 
has also demonstrated increased MMP-9 activity 
in endothelial cells under chronic hyperglycemia 
environments as compared with cells under 
acute hyperglycemia (24 hours).19 In addition to 
chronic state, acute hyperglycemia might have 
also contributed to increased MMP-9 levels since 
half of the patients had no history of diabetes.
Several factors may affect MMP-9 levels in 
type-2 diabetes mellitus, such as consumption 
of statins, fibrates, ACE inhibitors, angiotensin 
receptor blockers, calcium channel blockers and 
acetyl salicylic acid.23-25 Statins and fibrates are 
the most widely used drugs for the treatment of 
hyperlipidemia in diabetic patients. These drugs 
have antiinflammatory and antioxidant properties. 
They improve endothelial function and stabilize 
atherosclerotic plaque through modulation of 
extracellular matrix homeostasis and reduction 
of MMP concentration and activity.23 Acetyl 
Table 2. Prevalence ratio of high MMP-9 level in subjects with  and without hyperglycemia





hyperglycemia (n=38) Prevalence ratio CI 95% P value
High (>1014.25) 30 (41.6%) 22 (30.6%) 2.88 1.16–7.14 0.004
Low (≤1014.25) 4 (5.6%) 16 (22.2%)
CI=confidence interval
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salicylic acid blocks cyclooxygenase activity; 
therefore, reducing the synthesis of prostaglandin 
and controlling the activity of MMP.26 The 
effects of such medications in our study was 
difficult to assess because there was a lack of data 
regarding previous drugs taken by the subjects. 
However, since the previous diseases were 
comparable between subjects with and without 
hyperglycemia, we assumed that the impact of 
the drugs, if any, on MMP-9 levels were also 
comparable.
Our study showed a relationship between 
MMP-9 levels and hyperglycemia occurring 
in acute coronary syndrome. Patients with 
hyperglycemia had a prevalence ratio of 2.88 
for having high MMP-9 levels while suffering 
from acute coronary syndrome. High MMP-9 
levels may mediate the detrimental effects of 
hyperglycemia in acute coronary syndrome. 
Acute hyperglycemia exacerbates oxidative 
stress and RAGE production with subsequent 
MMP overexpression in the vascular wall.10 
Moreover, on-admission hyperglycemic state 
alone is also associated with worse outcomes 
in acute coronary syndromes.27 In combination 
with increased MMP-9 levels, these patients may 
have additional risk and burden for developing 
adverse events during hospitalisation. Further 
research should be performed to investigate the 
impact of hyperglycemia and increased MMP-9 
levels in acute coronary syndrome.
The limitations of our study were the small 
sample size in each group, the incomplete 
data regarding previous medications and the 
measurement of blood glucose levels which was 
only performed once on-admission. Further study 
to overcome the limitations should be done to 
validate our finding.
CONCLUSION
Serum MMP-9 levels is significantly higher 
in patients suffering from acute coronary 
syndrome with hyperglycemia compared to those 
without hyperglycemia.
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